Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Sun Pharma has made its play just three months after Checkpoint won FDA approval for PD-L1 inhibitor Unloxcyt (cosibelimab) ...

By Roger Cohen Reporting from Paris For decades a core objective of the Soviet Union was to “decouple” the United States from Europe. Decoupling, as it was called, would break the Western ...

Wolves became less protected in most of Europe on Friday as new conservation regulations came into force, except in three countries that objected to the move including the United Kingdom ...

Sir Keir Starmer is due to speak to European leaders on Friday, as the UK’s diplomatic push for peace in Ukraine continues. Prime Minister Sir Keir Starmer is meeting with European leaders (Paul ...

Regeneron Canada, a biotechnology company focused on developing treatments for serious diseases, has reached a pricing and funding agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...

MOSCOW -Russian officials and lawmakers on March 6 poured scorn on French President Emmanuel Macron for saying that Russia threatened Europe, and cautioned that such talk could lead the West ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Total Libtayo sales came in at $366.9 million ... was submitted to the FDA and a decision is expected by mid-2025. The European Commission (EC) approved Dupixent to treat eosinophilic esophagitis ...